Shuhua Yi

Chinese Academy of Medical Sciences & Peking Union Medical College — China

Earth and Planetary Sciences · Physical Sciences

36h-index3.8kcitations144works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cryospheric studies and observations(40), Climate change and permafrost(39), Remote Sensing in Agriculture(27), Land Use and Ecosystem Services(23), Ecology and Vegetation Dynamics Studies(19)

Publications144 total

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma ( <scp>CLL</scp> / <scp>SLL</scp> ): Results from the phase 3 study <scp>BRUIN CLL</scp> ‐321
British Journal of Haematology·2026Open Access
The Impact of Climate Change on Chorthippus dubius (Zubovski, 1898) Distribution in Alpine Grassland—A Case Study in the Qilian Mountain National Park, China
Agronomy·2025Open Access
Clinical characteristics and prognostic analysis of 52 cases of ALK-positive anaplastic large cell lymphoma
Blood·2025Open Access
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Blood·2025Open Access
BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Blood·2025Open Access
Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients
Blood·2025
Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy
Blood·2025Open Access
Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)
Blood·2025Open Access
3114 – TENT5C AS A TARGET OF CHROMATIN REMODELER SMARCA2 PARTICIPATES IN BTK INHIBITOR RESISTANCE IN MANTLE CELL LYMPHOMA BY REGULATING ATP METABOLISM
Experimental Hematology·2025
Livestock Dung Proxies Provide Insights into Grazing Density Quantification and Distribution
Animals·2025Open Access
IBCL-576: Long-Term Follow-Up of the Phase 2 ELM-2 Study: Efficacy and Survival Outcomes With Odronextamab in Relapsed/Refractory Follicular Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: IBCL-576 Long-Term Follow-Up of the Phase 2 ELM-2 Study: Efficacy and Survival Outcomes With Odronextamab in Relapsed/Refractory Follicular Lymphoma
Clinical Lymphoma Myeloma & Leukemia·2025
Development of a Cytogenetic Double-Hit Model for Survival Prediction in Multiple Myeloma
Cancers·2025Open Access
A multi-tiered representativeness framework mitigating spatial scale effects in FVC validation: UAV-based assessment of global products in Qinghai-Tibetan Plateau alpine grasslands
International Journal of Applied Earth Observation and Geoinformation·2025· 2 citedOpen Access
The Influencing Mechanism and Changing Evaluation of Plateau Pika Hazard: Implications for Grassland Management
Land Degradation and Development·2025· 1 cited
DVMDOSTEM v0.8.3: a terrestrial ecosystem model designed to represent arctic, boreal and permafrost ecosystem dynamics
The Journal of Open Source Software·2025Open Access
807 | TENT5C AS A TARGET OF CHROMATIN REMODELER SMARCA2 PARTICIPATES BTK INHIBITOR RESISTANCE IN MANTLE CELL LYMPHOMA BY REGULATING ATP METABOLISM
Hematological Oncology·2025Open Access
242 | LONG‐TERM EFFICACY AND SURVIVAL OUTCOMES WITH ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): 2‐YEAR FOLLOW‐UP FROM THE PHASE 2 ELM‐2 STUDY
Hematological Oncology·2025Open Access
A PVT-Insensitive 7-Bit Coarse-Fine Ratio-Metric Digital-to-Time Converter for Fractional-N Phase-Locked Loops in 65-nm CMOS
2025
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions
Expert Review of Hematology·2025· 4 cited
page 1 of 8Next →

Frequent Co-authors

Jianjun Chen(14), Yu Qin(13), Yongjian Ding(12), Baoping Meng(9), A. David McGuire(6), Yi Sun(6), Huifang Zhang(5), Baisheng Ye(5), Shilong Ren(5), Qin Yu(5), J. W. Harden(4), Yanyan Lv(4), M. Altaf Arain(3), Yan Qin(3), Xiaoyun Wang(3), Donghui Shangguan(3), Chuancheng Zhao(3), Zhaoye Zhou(3), Bo Xiang(3), Eric S. Kasischke(3)